Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Diagnostics Clinical care

By Our Powers Combined…

“Will Zika return? What pregnant women and others need to know about this frightening disease”

“1 in 7 babies exposed to Zika in the womb have health problems”

“A ‘perfect storm’ for the future spread of the Zika virus”

Viruses like Zika have been the subject of intense media attention, particularly since the widely publicized outbreaks in South America began. It’s well-known that fetuses and newborns who carry the virus are at risk of permanent health issues – but how can doctors conclusively identify those infected?

Felix Drexler, Head of the Virus Epidemiology Group at the Charité – Universitätsmedizin Berlin, explains that current diagnostic methods for Zika and similar viruses face one common denominator: low sensitivity. “This applies to molecular methods, because viremia is super low and super short-lived, and also antibody tests – the latter in particular in tropical areas,” he says. “People with multiple flavivirus infections mount weaker IgM responses, and these people are so full of antibodies against common flavivirus epitopes that serological test specificity diminishes greatly.”

These complications can lead to false-positive results – a dangerous situation in general, but especially so for patients in outbreak regions or those without quality health care. Women may choose to terminate a pregnancy that might otherwise be healthily carried to term – and, in cases where safe reproductive care is difficult to access, such choices can be fatal.

Why are false positives so prevalent? Partly laboratory contamination and partly low test specificity. Drexler and his colleagues experimented with using IgA as a marker for acute infection (rather than the standard IgM approach) and saw markedly increased sensitivity (1). “At least 50 percent in our study,” says Drexler. “IgM and IgA may jointly allow high sensitivity and specificity. IgG increases in paired sera add significantly to this.”

Combined antibody testing offers new diagnostic options for not only Zika, but also for other viruses, such as Middle East Respiratory Syndrome (MERS) coronavirus. If laboratory medicine professionals can distinguish between infections caused by different viruses, it helps patients and primary care providers to understand how best to proceed after diagnosis – hopefully, saving lives.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. FA Bozza et al., “Differential shedding and antibody kinetics of Zika and chikungunya viruses, Brazil”, Emerg Infect Dis, 25, 311 (2019). PMID: 30666934.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Application Notes
LC/MS/MS Method Package for Bile Acids Ver. 2

| Contributed by Shimadzu

Diagnostics Clinical care
Be Sure, Today and Tomorrow—LC-MS in Clinical Research

| Contributed by Thermo Fisher Scientific

Diagnostics Screening and monitoring
Five Reasons to implement LC-MS platforms for your laboratory developed tests

| Contributed by Thermo Fisher Scientific

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine